MARINUS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.335 USD | +3.49% |
|
+1.58% | -87.85% |
| May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
| May. 17 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 39.35M | Sales 2025 * | 58.17M | Capitalization | 70.86M |
|---|---|---|---|---|---|
| Net income 2024 * | -120M | Net income 2025 * | -77M | EV / Sales 2024 * | -1.44 x |
| Net cash position 2024 * | 127M | Net cash position 2025 * | 54.53M | EV / Sales 2025 * | 0.28 x |
| P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-1.24
x | Employees | 166 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on Marinus Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -3.01% | ||
| 1 week | -3.01% | ||
| Current month | -8.51% | ||
| 1 month | -12.54% | ||
| 3 months | -86.59% | ||
| 6 months | -78.78% | ||
| Current year | -88.13% |
1 week
1.27
1.39
1 month
1.271.77
Current year
1.1111.26
1 year
1.1111.26
3 years
1.1119.83
5 years
1.1120.04
10 years
1.1182.88
| Managers | Title | Age | Since |
|---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 21-04-11 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 19-11-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 08-11-30 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Elan Ezickson
BRD | Director/Board Member | 60 | 19-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 1.33 | +3.10% | 123 761 |
| 24-05-22 | 1.29 | -3.01% | 879,205 |
| 24-05-21 | 1.33 | -1.48% | 1,617,246 |
| 24-05-20 | 1.35 | +1.50% | 1,311,268 |
| 24-05-17 | 1.33 | +2.31% | 1,305,323 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotes
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.29
USD
Average target price
6.667
USD
Spread / Average Target
+416.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -88.13% | 70.86M | |
| +37.74% | 723B | |
| +34.39% | 595B | |
| -2.07% | 369B | |
| +20.25% | 332B | |
| +2.99% | 282B | |
| +17.04% | 244B | |
| +9.80% | 208B | |
| -4.17% | 205B | |
| +2.81% | 168B |
- Stock Market
- Equities
- MRNS Stock
